Company intelligence / Profile preview

Boneshaker

Redwood City, California, United Statesboneshakermmxii.com ↗

Ownership: Private
Development stage: Other

Overview

The company's lead product, Osteoboost, has completed clinical trials demonstrating significant reduction in bone breakdown activity and slowing of bone density loss. It achieved high user adherence (>80%) and zero serious adverse events. The device received FDA clearance as the first non-pharmacological prescription wearable for osteopenia and osteoporosis prevention/treatment. Public launch expected soon.

Therapeutic areas: EndocrinologyWomen's Health
Modalities: DeviceNon-pharmacological therapyWearable medical device therapy
Industry: Therapeutic Medical Devices

Partnerships

Esplanade Ventures (investor/partner)

Beyond the preview

Go deeper on Boneshaker.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boneshaker.

Explore the full profile